Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to

Read the full 286 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE